← All trials
NCT03592472
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 17, 2018
- Primary completion
- Jan 17, 2022
- Completion date
- Jan 17, 2022
- First posted
- —
- Last posted
- —
- Enrollment
- 413
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Xynomic Pharmaceuticals, Inc.Lead sponsor
- University of California, San FranciscoStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.